Stifel Maintains Buy on Krystal Biotech, Raises Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha maintains a Buy rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $102 to $145.
May 24, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha maintains a Buy rating on Krystal Biotech and raises the price target from $102 to $145.
The news of Stifel maintaining a Buy rating and raising the price target for Krystal Biotech (KRYS) from $102 to $145 indicates a positive outlook for the company's stock. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100